跳转至内容
Merck
CN

Y0001649

阿立哌唑

European Pharmacopoeia (EP) Reference Standard

别名:

7-{4-[4-(2,3-二氯苯基)-L-哌嗪基]丁氧基}-3,4-二氢-2(1H)-喹啉酮

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C23H27Cl2N3O2
化学文摘社编号:
分子量:
448.39
UNSPSC Code:
41116107
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

阿立哌唑, European Pharmacopoeia (EP) Reference Standard

SMILES string

Clc1c(cccc1N2CCN(CC2)CCCCOc3cc4c(cc3)CCC(=O)N4)Cl

InChI

1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)

InChI key

CEUORZQYGODEFX-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

aripiprazole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

正在寻找类似产品? 访问 产品对比指南

Application

Aripiprazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Andrea de Bartolomeis et al.
Expert opinion on pharmacotherapy, 13(14), 2027-2036 (2012-09-06)
Bipolar disorder is characterized by a complex set of symptoms, including recurrent manic, depressive or mixed episodes. Acute and long-term treatment of patients with bipolar disorder is mandatory to prevent symptom relapse and episode recurrences. Outcomes with monotherapy are often
Peter Paul De Deyn et al.
Expert opinion on pharmacotherapy, 14(4), 459-474 (2013-01-29)
Psychosis is a common and difficult to treat symptom in Alzheimer's disease (AD). It is a cause of diminished quality of life and caregiver distress. Atypical antipsychotics are frequently used for the treatment of dementia-related psychosis, despite FDA warnings because
Manit Srisurapanont et al.
Journal of psychiatric research, 62, 38-47 (2015-01-27)
Limited options are available for clozapine-resistant schizophrenia and intolerable side effects of clozapine. We conducted a systematic review of randomized-controlled trials (RCTs) to determine the efficacy and safety of aripiprazole augmentation of clozapine for schizophrenia. Electronic databases searched included PubMed
Rachel Brown et al.
The Cochrane database of systematic reviews, 12(12), CD005000-CD005000 (2013-12-19)
Bipolar disorder is a mental disorder characterised by episodes of elevated or irritable mood (manic or hypomanic episodes) and episodes of low mood and loss of energy (depressive episodes). Drug treatment is the first-line treatment for acute mania with the
Lesley Uttley et al.
PharmacoEconomics, 31(11), 981-990 (2013-10-05)
As part of its single technology process, the National Institute for Health and Care Excellence (NICE) invited the manufacturers of aripiprazole (Otsuka Pharmaceutical Co. and Bristol Myers Squibb) to submit evidence of the clinical and cost effectiveness of aripiprazole for

实验方案

Aripiprazole, an atypical antipsychotic, treats schizophrenia, bipolar disorder, and major depressive disorder.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持